DTIL · Precision Biosciences Inc · Metrics
$6.55
+0.36 (+5.82%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$170.85M
Shares
27.60M
Volume · Oct 20
210.91K
Avg daily vol (3M)
265.29K
DTIL metrics
75 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$6.19
Market cap
$170.85M
Price action
20 metricsPrice change (1W)
-5.2%
Price change (30D)
-4.8%
Price change (3M)
-15.9%
Price change (6M)
-18.3%
Price change (YTD)
+48.8%
Price change (1Y)
-10.3%
Trailing year
Price change (5Y)
—
52-week high
$9.28
52-week low
$3.57
Change from 52-week high
-33.3%
Change from 52-week low
+73.4%
Annualized volatility
70.2%
Annualized volatility (3M)
56.3%
Beta
1.1
RSI (14D)
44.2
Price vs SMA 50
-12.4%
Price vs SMA 200
-3.5%
Avg volume (3M)
265,285
Relative volume
0.7
Average dollar volume
$1.90M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
27.60M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.8×
reciprocal yield 26.4%
P / book
3.8
reciprocal yield 26.5%
FCF yield
-30.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-30.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-1.0×
EV / revenue historical average (5Y)
-1.0×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-02-11
Profitability
9 metricsGross margin
—
Operating margin
-80.8%
Trailing 12 months
Net margin
-117.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$36.40M
Net income (TTM)
−$52.73M
Trailing 12 months
Diluted EPS (TTM)
$-1.23
FCF margin
-115.3%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
-738.0%
Revenue (TTM)
$45.05M
Trailing 12 months
EPS growth YoY
-442.3%
Shares change YoY
+134.1%
Year over year · more shares
Revenue CAGR (3Y)
+10.9%
Revenue CAGR (5Y)
+7.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-116.4%
Return on assets
-41.9%
Debt / equity
—
Current ratio
12.8
EBITDA (TTM)
−$35.15M
Free cash flow (TTM)
−$51.94M
Quick ratio
12.8
Interest coverage
-27.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$86.08M
Total assets
$125.92M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$51.90M
Capital expenditures (TTM)
$37,000
R&D (TTM)
$53.32M
SG&A (TTM)
—
Stock compensation (TTM)
$7.82M
R&D / revenue
118.3%
Stock compensation / revenue
17.4%
Ownership (13F)
9 metrics13F filers
96
13F filer change QoQ
+18
Institutional ownership
64.1%
Conviction holders (share of 13F filers)
3.2%
Crowding (high-turnover and private-fund holders)
38.5%
Private-fund adviser ownership
37.6%
Active holders' share change QoQ
-5.9%
Holder tenure
5.9
Price vs estimated holder cost
+34.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
7.9%
Short interest
3 metricsShort interest
9.1%
Latest settlement · 8.8 days to cover
Days to cover
8.8d
Short-squeeze score
72 / 100
Insider activity
2 metricsNet insider buying (90D)
$29,501
Insider-sentiment score
83 / 100
Risk flags
1 metricsGoing concern
—